Reviewed by Dr. Fischer

Scleroderma (also called systemic sclerosis) is a rare disease characterized most often by skin thickening.  Scleroderma also may involve internal organs and often leads to intestinal, kidney, lung and heart problems. It is a chronic disease, which means it lasts a long time.

When scleroderma only involves the skin, it is called localized or linear scleroderma or morphea. When there is internal organ involvement, it is called generalized scleroderma or systemic sclerosis. Early diagnosis and treatment are essential to help prevent many of the complications of scleroderma.

 

Programs & Services
We seek to transform patient care from reactive to being both proactive and personalized.

View Directory of Programs and Services

Clinical Trials

Scleroderma Lung Study II (SLSII)

The objective is to determine if a 2-year course of Mycophenolate (CellCept) will be safer and more effective than treatment with a 1-year course of oral Cyclophosphamide (Cytoxan) in patients suffering from active and symptomatic Scleroderma Interstitial Lung Disease.

Patient Groups:
150 patients will be enrolled from 12 sites with 1/2 of the patients receiving CellCept and the other 1/2 receiving Cytoxan.

Study Visits:
Approximately 28 visits over a 2-year period.

Learn More